HIGH-DOSE INTRAVENOUS METHOTREXATE WITH HIGH-FLUX HAEMODIALYSIS IN TREATMENT OF POST-TRANSPLANT, CENTRAL NERVOUS SYSTEM LYMPHOMA WITH END-STAGE KIDNEY DISEASE

E VAUGHAN1, J YEUNG2, C BROWN2,S CHADBAN1, N THIAGARAJAH2, J SAUNDERS1

1Renal Department Royal Prince Alfred Hospital, Sydney, NSW; 2Institute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW

Background: High-dose intravenous methotrexate (HD-MTX) is an integral part in primary central nervous system (CNS) lymphoma treatment. Predominant renal excretion of methotrexate limits its use in patients with end-stage kidney disease (ESKD). We report a case of post-transplant CNS lymphoma treated with methotrexate and extended hours high-flux haemodialysis.

Case Report: A 41-year-old man with a cadaveric renal transplant of 26 years for reflux nephropathy, presented with headache and absence seizures despite previously well-controlled epilepsy. He had chronic allograft nephropathy on weaning triple therapy immunosuppression. Multi-focal lesions found on cerebral magnetic resonance imaging (MRI) were biopsied to confirm monomorphic post-transplant lymphoproliferative disorder (PTLD) without metastatic disease. Transition to haemodialysis was complicated by increased clearance of anti-epileptic drugs (AEDs) leading to partial seizures. Whole brain radiotherapy (WBRT) was undertaken for initial control, followed by three cycles of dose-escalated methotrexate. This was followed by eight-hour high cut-off haemodialysis, and leucovorin rescue with close monitoring of methotrexate levels and increased dose of AEDs. Follow-up MRI, and neurological PET-CT confirmed remission 6 weeks post-treatment.

Methotrexate is primarily cleared in the urine, which limits its use in ESKD due to nephrotoxicity and myelosuppression. In conjunction with high-flux haemodialysis, HD-MTX ranging from 1 to 9.5g/m2 has been scarcely described for solid organ and haematological malignancies. Confounding management issues included the associated clearance of AEDs with extended-hours haemodialysis. This was managed with intra-dialytic drug dosing and up-titration. Adequate clearance of methotrexate occurred despite increased dosing. Residual renal function may have contributed to prompt drug clearance.

Conclusions: For CNS lymphoma, HD-MTX with high-flux haemodialysis should be considered a viable option in candidates with ESKD without other contraindications.

About ANZSN

The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

/wp-content/uploads/2017/08/Conference-Design-400×400.png

© 2015 - 2016 Conference Design Pty Ltd